


Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations

*Principles, Methods, and Applications
in the Pharmaceutical Industry*

Sheila Annie Peters



PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATIONS

Principles, Methods,
and Applications in the
Pharmaceutical Industry



WILEY

JOHN WILEY & SONS, INC.

Copyright © 2012 by John Wiley & Sons. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey

Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, 201-748-6011, fax 201-748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at 877-762-2974, outside the United States at 317-572-3993 or fax 317-572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Peters, Sheila Annie.

Physiologically-based pharmacokinetic (PBPK) modeling and simulations : principles, methods, and applications in the pharmaceutical industry / Sheila Annie Peters.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-48406-7 (cloth)

1. Pharmacokinetics—Mathematical models. 2. Drugs—Design—Mathematical models. I. Title.

[DNLM: 1. Pharmacokinetics. 2. Drug Design. 3. Models, Biological. QV 38]

RM301.5.P48 2011

615'.7—dc23

2011019939

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

PHYSIOLOGICALLY-BASED
PHARMACOKINETIC
(PBPK) MODELING
AND SIMULATIONS



*This book is dedicated to my parents, friends, and
Alfred and Christina who have always believed in me.*

PREFACE

Physiologically-based pharmacokinetic (PBPK) modeling has made rapid strides in the pharmaceutical industry in the last decade or so, thanks to an increasing awareness of the potential applications of this powerful tool. As pharmaceutical companies are working to integrate PBPK modeling into their lead selection cycle and clinical development, the availability of commercial software has played a key role in enabling even those without modeling expertise to come on board. However, this entails the risk of misuse, misinterpretation, or overinterpretation of modeling results, if the principles and underlying assumptions of PBPK modeling are not clearly understood by the users. Today, the challenge facing pharmaceutical companies is educating and training their staff to achieve an effective application of PBPK/ pharmacodynamics (PD) in projects across the value chain. In the future, providers of education should take on the responsibility of making available, modelers with appropriate skills. Given the complexity of PBPK modeling, it is certainly not an easy task for a beginner with little or no background to understand the model structure and to be aware of its limitations. The lack of a textbook on PBPK has been a further deterrent. It is hoped that this book will serve as a primary source of information on the principles, methods, and applications of PBPK modeling, exposing the power of a largely hidden and unexplored tool. Applications in the pharma sector will be the main focus, as applications in environmental toxicology and human health risk assessment have already been the subject of a previous publication.

Target audiences for the book include students and researchers in academia, apart from scientists and modelers in the pharmaceutical industry. The book can also be a resource for R&D managers in the pharmaceutical industry, seeking a quick overview of the benefits of applying PBPK modeling along the drug discovery and development value chain. An understanding of the principles of PBPK modeling by R&D management would enhance their acceptance and appreciation, which in turn can translate to effective managerial support for PBPK modeling. This book is intended to serve the interests of both the general reader, who may only want an overview of the applications of PBPK modeling without wanting an in-depth understanding of the underlying methods, and the specialist reader, who may be interested to build new models. For the general reader, keywords appear in boldface and are explained at the end of the chapters. No particular expertise is assumed in order to keep the book accessible to a diverse audience. An extensive list of bibliographic

references will help the specialist reader to build on the concepts developed in the book. A generous use of figures to illustrate concepts will help the reader gain valuable insights into this fascinating subject.

The book comprises two parts. The first part provides a detailed and systematic treatment of the principles behind physiological modeling of pharmacokinetic processes, interindividual variability, and drug interactions for small-molecule drugs and biologics. The second part exposes the reader to the powerful applications of PBPK modeling along the value chain in drug discovery and development.

SHEILA ANNIE PETERS

ACKNOWLEDGMENTS

I would like to thank Bernd Meibohm and several of my colleagues at AstraZeneca—Balaji Agoram, Ulf Bredberg, James Bird, Hugues Dolgos, Ulf Ericsson, Marcus Friden, Rasmus Jansson Löfmark, Martin Hayes, Sarah Kelly, Maria Learoyd, James Tucker, Pete Webborn, and Anna-Lena Ungell, who helped review the chapters. I would like to record my deep appreciation for the meticulous work of Tony Johansson, whose positive attitude and hard work has resulted in the excellent figures in this book. This work would not have been possible without the consistent support extended by my friends and family.

S. A. P.

CONTENTS

Preface	xv
Acknowledgments	xvii
SECTION I. PRINCIPLES AND METHODS	1
1 MODELING IN THE PHARMACEUTICAL INDUSTRY	3
1.1 Introduction	3
1.2 Modeling Approaches	4
1.3 Steps Needed to Maximize Effective Integration of Models into R&D Workflow	7
1.4 Scope of the Book	8
Keywords	10
References	12
2 PHYSIOLOGICALLY-BASED MODELING	13
2.1 Introduction	13
2.2 Examples of Physiological Modeling	14
2.3 Need for Physiological Models in the Pharmaceutical Industry	15
2.4 Organs as Compartments	15
2.5 Bottom-Up vs. Top-Down Modeling in Pharmacokinetics	16
References	16
3 REVIEW OF PHARMACOKINETIC PRINCIPLES	17
3.1 Introduction	18
3.2 Routes of Administration	18
3.3 Drug Disposition	18
3.3.1 Absorption	18

3.3.2	Plasma Protein Binding, Blood–Plasma Ratio	20
3.3.3	Distribution, Elimination, Half-Life, and Clearance	23
3.3.4	Role of Transporters in ADME	29
3.4	Linear and Nonlinear Pharmacokinetics	34
3.5	Steady-State Pharmacokinetics	34
3.6	Dose Estimations	37
3.7	Successful PK Optimization in Drug Discovery	40
	Keywords	40
	References	41

4 PHYSIOLOGICAL MODEL FOR ABSORPTION 43

4.1	Introduction	44
4.2	Drug Absorption and Gut Bioavailability	44
4.2.1	Solubility and Dissolution Rate	44
4.2.2	Permeability: Transcellular, Paracellular, and Carrier-Mediated Pathways	51
4.2.3	Barriers to Membrane Transport—Luminal Degradation, Efflux, and Gut Metabolism	53
4.3	Factors Affecting Drug Absorption and Gut Bioavailability	56
4.3.1	Physiological Factors Affecting Oral Drug Absorption and Species Differences in Physiology	56
4.3.2	Compound-Dependent Factors	62
4.3.3	Formulation-Dependent Factors	63
4.4	<i>In Silico</i> Predictions of Passive Permeability and Solubility	66
4.4.1	<i>In Silico</i> Models for Permeability	66
4.4.2	<i>In Silico</i> Models for Solubility	67
4.5	Measurement of Permeability, Solubility, Luminal Stability, Efflux, and Intestinal Metabolism	67
4.5.1	<i>In Vitro</i> , <i>in Situ</i> and <i>in Vivo</i> Assays for Permeability	67
4.5.2	Measurement of Thermodynamic or Equilibrium Solubility	72
4.5.3	Luminal Stability	74
4.5.4	Efflux	74
4.5.5	<i>In Vitro</i> Models for Estimating Extent of Gut Metabolism	76
4.6	Absorption Modeling	76
	Keywords	83
	References	84

5	PHYSIOLOGICAL MODEL FOR DISTRIBUTION	89
5.1	Introduction	90
5.2	Factors Affecting Tissue Distribution of Xenobiotics	91
5.2.1	Physiological Factors and Species Differences in Physiology	91
5.2.2	Compound-Dependent Factors	98
5.3	<i>In Silico</i> Models of Tissue Partition Coefficients	98
5.4	Measurement of Parameters Representing Rate and Extent of Tissue Distribution	105
5.4.1	Assessment of Rate and Extent of Brain Penetration	105
5.5	Physiological Model for Drug Distribution	110
5.6	Drug Concentrations at Site of Action	111
	Keywords	114
	References	115
6	PHYSIOLOGICAL MODELS FOR DRUG METABOLISM AND EXCRETION	119
6.1	Introduction	119
6.2	Factors Affecting Drug Metabolism and Excretion of Xenobiotics	120
6.3	Models for Hepatobiliary Elimination and Renal Excretion	124
6.3.1	<i>In Silico</i> Models	124
6.3.2	<i>In Vitro</i> Models for Hepatic Metabolism	125
6.3.3	<i>In Vitro</i> Models for Transporters	127
6.4	Physiological Models	136
6.4.1	Hepatobiliary Elimination of Parent Drug and Metabolites	136
6.4.2	Renal Excretion	141
	References	144
7	GENERIC WHOLE-BODY PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING	153
7.1	Introduction	153
7.2	Structure of a Generic Whole Body PBPK Model	154
7.3	Model Assumptions	157
7.4	Commercial PBPK Software	158
	References	159

8 VARIABILITY, UNCERTAINTY, AND SENSITIVITY ANALYSIS 161

8.1	Introduction	161
8.2	Need for Uncertainty Analysis	162
8.3	Sources of Physiological, Anatomical, Enzymatic, and Transporter Variability	163
8.4	Modeling Uncertainty and Population Variability with Monte Carlo Simulations	169
8.5	Sensitivity Analysis	172
8.6	Conclusions	174
	Keywords	174
	References	175

9 EVALUATION OF DRUG–DRUG INTERACTION RISK WITH PBPK MODELS 183

9.1	Introduction	184
9.2	Factors Affecting Drug–Drug Interactions	186
9.3	<i>In Vitro</i> Methods to Evaluate Drug–Drug Interactions	190
9.3.1	Candidate Drug as a Potential Inhibitor	190
9.3.2	Candidate Drug as a Potential Victim of Inhibition	192
9.4	Static Models to Evaluate Drug–Drug Interactions	193
9.5	PBPK Models to Evaluate Drug–Drug Interactions	195
9.5.1	Intrinsic Clearance of Victim (V) in the Absence of Inhibitor or Inducer	195
9.5.2	Intrinsic Clearance of Victim (V) in the Presence of Inhibitor	196
9.5.3	Time-Dependent Changes in the Abundance of an Enzyme Isoform Inhibited by an MBI	197
9.5.4	Intrinsic Clearance of Victim (V) in the Presence of Inducer	197
9.6	Comparison of PBPK Models and Static Models for the Evaluation of Drug–Drug Interactions	198
	Keywords	201
	References	202

10 PHYSIOLOGICALLY-BASED PHARMACOKINETICS OF BIOTHERAPEUTICS 209

10.1	Introduction	210
10.2	Therapeutic Proteins	210

10.2.1 Peptides and Proteins	210
10.2.2 Monoclonal Antibodies	212
10.3 Pharmacokinetics of Therapeutic Proteins	214
10.3.1 Peptides and Proteins	215
10.3.2 Monoclonal Antibodies	224
10.4 PBPK/PD Modeling for Therapeutic Proteins	230
10.4.1 Need for PBPK Modeling for Therapeutic Proteins	230
10.4.2 PBPK Modeling for Therapeutic Proteins	231
10.4.3 Pharmacokinetic Scaling	239
10.4.4 Applications of PBPK Models of Therapeutic Proteins	242
10.4.5 PBPK Integration with Pharmacodynamics	244
10.5 Antisense Oligonucleotides and RNA Interference	245
10.5.1 Antisense Oligonucleotides (ASOs)	245
10.5.2 Ribonucleic Acid Interference (RNAi)	245
10.5.3 Pharmacokinetics of ASOs ⁵⁰ and Double-Stranded RNAs	247
10.5.4 Design and Modifications of ASOs to Improve Target Affinity and PD: the First, Second, and Third Generation ASOs	249
10.5.5 Integration of PK/PBPK and PD Modeling	253
Keywords	254
References	256

SECTION II. APPLICATIONS IN THE PHARMACEUTICAL INDUSTRY 261

11 DATA INTEGRATION AND SENSITIVITY ANALYSIS 263

11.1 Introduction	263
11.2 Examples of Data Integration with PBPK Modeling	264
11.3 Examples of Sensitivity Analysis with PBPK Modeling	267
References	271

12 HYPOTHESIS GENERATION AND PHARMACOKINETIC PREDICTIONS 273

12.1 Introduction	274
12.2 PBPK Simulations of Pharmacokinetic Profiles for Hypothesis Generation and Testing	274

12.2.1 Methodology	274
12.2.2 <i>In Vivo</i> Solubility	278
12.2.3 Delayed Gastric Emptying	280
12.2.4 Regional Variation in Intestinal Loss: Gut Wall Metabolism, Intestinal Efflux, and Luminal Degradation	282
12.2.5 Enterohepatic Recirculation	284
12.2.6 Inhibition of Drug-Metabolizing Enzymes	286
12.2.7 Inhibition of Hepatic Uptake	286
12.2.8 Inhibition of Hepatobiliary Efflux	290
12.3 Pharmacokinetic Predictions	293
12.3.1 Human Predictions from Preclinical Data	293
12.3.2 Pharmacokinetic Predictions in Clinical Development	293
References	294

13 INTEGRATION OF PBPK AND PHARMACODYNAMICS	299
13.1 Introduction	300
13.2 Pharmacodynamic Principles	300
13.2.1 Pharmacological Targets and Drug Action	300
13.2.2 Functional Adaptation Processes: Tolerance, Sensitization, and Rebound (Fig 13.2)	301
13.3 Pharmacodynamic Modeling	307
13.3.1 Concentration–Effect, Dose–Response Curves, and Sigmoid E_{\max} Models	307
13.3.2 Mechanism-Based PD Modeling	315
13.3.3 Simple Direct Effects	315
13.3.4 Models Accommodating Delayed Pharmacological Response	321
13.3.5 Models Accommodating Nonlinearity in Pharmacological Response with Respect to Time	332
13.4 Pharmacokinetic Modeling: Compartmental PK and PBPK	335
13.5 Integration of PK or PBPK with PD Modeling	335
13.6 Reasons for Poor PK/PD Correlation	339
13.7 Applications of PK or PBPK/PD Modeling in Drug Discovery and Development	340
13.7.1 Need for a Mechanistic PBPK/PD Integration	341

13.7.2 Applications of PK or PBPK/PD in Drug Discovery	342
13.7.3 Applications of PK or PBPK/PD in Drug Development	360
13.8 Regulatory Perspective	370
13.9 Conclusions	371
Keywords	372
References	376
14 PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF POPULATIONS	383
14.1 Introduction	383
14.2 Population Modeling with PBPK	384
14.3 Healthy to Target Patient Population: Impact of Disease on Pharmacokinetics	386
14.4 Modeling Subpopulations: Impact of Age, Gender, Co-morbidities, and Genetics on Pharmacokinetics	389
14.5 Personalized Medicine with PBPK/PD	392
Keyword	395
References	396
15 PBPK MODELS ALONG THE DRUG DISCOVERY AND DEVELOPMENT VALUE CHAIN	401
15.1 Summary of Applications of PBPK Models along Value Chain	401
15.2 Obstacles and Future Directions for PBPK Modeling	403
Keyword	405
References	405
Appendices	407
Index	423

SECTION I

PRINCIPLES AND METHODS
